1. Rodriguez LL, Grubman MJ. Foot and mouth disease virus vaccines. Vaccine. 2009; 27:Suppl 4. D90–D94.
Article
2. Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev. 2004; 17:465–493.
Article
3. Pacheco JM, Arzt J, Rodriguez LL. Early events in the pathogenesis of foot-and-mouth disease in cattle after controlled aerosol exposure. Vet J. 2010; 183:46–53.
Article
4. Sutmoller P, Barteling SS, Olascoaga RC, Sumption KJ. Control and eradication of foot-and-mouth disease. Virus Res. 2003; 91:101–144.
Article
5. Moraes MP, Mayr GA, Mason PW, Grubman MJ. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine. 2002; 20:1631–1639.
Article
6. Bachrach HL. Foot-and-mouth disease. Annu Rev Microbiol. 1968; 22:201–244.
Article
7. Pariente N, Sierra S, Airaksinen A. Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res. 2005; 107:183–193.
Article
8. Belsham GJ. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure. Prog Biophys Mol Biol. 1993; 60:241–260.
Article
9. Grubman MJ, Zellner M, Bablanian G, Mason PW, Piccone ME. Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus. Virology. 1995; 213:581–589.
Article
10. Park JH. Requirements for improved vaccines against foot-and-mouth disease epidemics. Clin Exp Vaccine Res. 2013; 2:8–18.
Article
11. Mason PW, Piccone ME, McKenna TS, Chinsangaram J, Grubman MJ. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology. 1997; 227:96–102.
Article
12. Almeida MR, Rieder E, Chinsangaram J, et al. Construction and evaluation of an attenuated vaccine for foot-and-mouth disease: difficulty adapting the leader proteinase-deleted strategy to the serotype O1 virus. Virus Res. 1998; 55:49–60.
Article
13. Kleid DG, Yansura D, Small B, et al. Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science. 1981; 214:1125–1129.
Article
14. Kleid DG. Using genetically engineered bacteria for vaccine production. Ann N Y Acad Sci. 1983; 413:23–30.
Article
15. Bittle JL, Houghten RA, Alexander H, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature. 1982; 298:30–33.
Article
16. DiMarchi R, Brooke G, Gale C, Cracknell V, Doel T, Mowat N. Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science. 1986; 232:639–641.
Article
17. Ward G, Rieder E, Mason PW. Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J Virol. 1997; 71:7442–7447.
Article
18. Wong HT, Cheng SC, Chan EW, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection. Virology. 2000; 278:27–35.
Article
19. Dus Santos MJ, Wigdorovitz A, Trono K, et al. A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants. Vaccine. 2002; 20:1141–1147.
Article
20. Carrillo C, Wigdorovitz A, Oliveros JC, et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J Virol. 1998; 72:1688–1690.
Article
21. Guo C, Zhang C, Zheng H, Huang Y. Recombinant adenovirus expression of FMDV P1-2A and 3C protein and its immune response in mice. Res Vet Sci. 2013; 95:736–741.
Article
22. Mayr GA, O'Donnell V, Chinsangaram J, Mason PW, Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine. 2001; 19:2152–2162.
Article
23. Mayr GA, Chinsangaram J, Grubman MJ. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology. 1999; 263:496–506.
Article
24. Berinstein A, Tami C, Taboga O, Smitsaart E, Carrillo E. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus. Vaccine. 2000; 18:2231–2238.
Article
25. Zheng M, Jin N, Zhang H, et al. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus. J Virol Methods. 2006; 136:230–237.
Article
26. Zhang K, Huang J, Wang Q, et al. Recombinant pseudorabies virus expressing P12A and 3C of FMDV can partially protect piglets against FMDV challenge. Res Vet Sci. 2011; 91:90–94.
Article
27. Li Z, Yi Y, Yin X, Zhang Z, Liu J. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. PLoS One. 2008; 3:e2273.
Article
28. Mohana Subramanian B, Madhanmohan M, Sriraman R, et al. Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency. Antiviral Res. 2012; 96:288–295.
Article
29. Park JH, Lee KN, Ko YJ, et al. Control of foot-and-mouth disease during 2010-2011 epidemic, South Korea. Emerg Infect Dis. 2013; 19:655–659.
Article
30. Sanz-Parra A, Jimenez-Clavero MA, Garcia-Briones MM, Blanco E, Sobrino F, Ley V. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology. 1999; 259:129–134.
Article
31. Saiz M, Nunez JI, Jimenez-Clavero MA, Baranowski E, Sobrino F. Foot-and-mouth disease virus: biology and prospects for disease control. Microbes Infect. 2002; 4:1183–1192.
Article
32. Lu Z, Bao H, Cao Y, et al. Protection of guinea pigs and swine by a recombinant adenovirus expressing O serotype of foot-and-mouth disease virus whole capsid and 3C protease. Vaccine. 2008; 26:Suppl 6. G48–G53.
Article
33. Bhat SA, Saravanan P, Hosamani M, et al. Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge. Res Vet Sci. 2013; 95:1217–1223.
Article
34. Zhang L, Zhang J, Chen HT, et al. Research in advance for FMD novel vaccines. Virol J. 2011; 8:268.
Article
35. Wang FX, Song N, Chen LZ, Cheng SP, Wu H, Wen YJ. Non-structural protein 2 of the porcine reproductive and respiratory syndrome (PRRS) virus: a crucial protein in viral pathogenesis, immunity and diagnosis. Res Vet Sci. 2013; 95:1–7.
Article
36. Xu YZ, Zhou YJ, Zhang SR, et al. Stable expression of foreign gene in nonessential region of nonstructural protein 2 (nsp2) of porcine reproductive and respiratory syndrome virus: applications for marker vaccine design. Vet Microbiol. 2012; 159:1–10.
Article
37. Yu D, Lv J, Sun Z, Zheng H, Lu J, Yuan S. Reverse genetic manipulation of the overlapping coding regions for structural proteins of the type II porcine reproductive and respiratory syndrome virus. Virology. 2009; 383:22–31.
Article
38. Pei Y, Hodgins DC, Wu J, et al. Porcine reproductive and respiratory syndrome virus as a vector: immunogenicity of green fluorescent protein and porcine circovirus type 2 capsid expressed from dedicated subgenomic RNAs. Virology. 2009; 389:91–99.
Article
39. Zimmer G. RNA replicons: a new approach for influenza virus immunoprophylaxis. Viruses. 2010; 2:413–434.
Article
40. Huang Q, Yao Q, Fan H, Xiao S, Si Y, Chen H. Development of a vaccine vector based on a subgenomic replicon of porcine reproductive and respiratory syndrome virus. J Virol Methods. 2009; 160:22–28.
Article